debate: drug of choice for exon 19 del egfr mutant nsclc - afatinib
Published 9 years ago • 2.6K plays • Length 16:22Download video MP4
Download video MP3
Similar videos
-
13:26
debate: drug of choice for exon 19 del egfr mutant nsclc - any egfr tki
-
14:30
adjuvant therapy for egfr mutant nsclc
-
20:24
targeted treatment with egfr tkis: front line options
-
20:35
tki-resistant egfr-mutant nsclc
-
21:35
long term management of egfr-mutant nsclc -tsao
-
1:25
dr. chachoua on afatinib for exon 19 mutation in lung cancer
-
23:10
egfr mutation positive tumors: treatment strategies in front line and at relapse
-
58:32
graft-versus-host disease: gastrointestinal tract (gi) and liver
-
5:51
the daily debate - cell therapy in children
-
15:14
sg-anzics 2019: debate: niv vs hfnc. which to use, when?
-
10:06
debate: what is the optimal timing for egfr-targeted therapy? - favor frontline therapy
-
37:23
nsclc: integrating egfr-inhibiting therapies into clinical pathways for first-line treatment
-
1:47
dr. west on fda approval of afatinib in nsclc with rare egfr mutations
-
5:47
egfr tkis for upfront treatment of nsclc
-
10:05
debate: what is the optimal timing for egfr-targeted therapy? - favor maintenance
-
19:53
managing progression in egfr-mutant nsclc patients: potential impact of 2nd and 3rd generation tkis?
-
21:09
mechanisms of resistance to egfr tki and new treatment strategies
-
44:03
egfr: the challenge of primary and secondary resistance
-
4:06
afatinib in patients with uncommon egfr mutations
-
3:47
afatinib therapy for uncommon egfr alterations in nsclc
-
16:27
debate: molecular profiling beyond egfr/alk - must be the standard